成本最小化分析和预算影响分析关于皮下纳塔利祖马布在意大利复发性转移性多发性硬化症中的使用
Luca Prosperini1, Lorenzo Pradelli2, Laura Santoni3
1S. Camillo-Forlanini Hospital, Rome, Italy.
ClinicoEconomics and outcomes research : CEOR
|April 16, 2025
概括
与静脉注射相比,皮下纳塔利祖马布可为多发性硬化症患者提供显著的成本节省. 这种转换通过降低整体医疗保健费用,使医疗保健提供者,患者和社会受益.
科学领域:
- 药物经济学 药物经济学
- 多发性硬化症的治疗方法
- 卫生技术评估 卫生技术评估
背景情况:
- 静脉注射 (IV) 纳塔利祖马布是一种已知的多发性硬化症 (MS) 治疗方法.
- 皮下 (SC) 纳塔利祖马布提供了一个替代的给药途径.
- 经济评估对于评估新治疗方式的价值至关重要.
研究的目的:
- 估计意大利SC与IV纳塔利祖马布的经济和财务影响.
- 从多个角度 (MS中心,患者,社会) 进行管理时间和成本的比较.
主要方法:
- 使用基于REFINE研究数据的马尔科夫模型进行成本最小化分析 (CMA).
- 预算影响分析 (BIA) 采用成本计算器方法,跨越3年.
- 从关于行政资源消耗和成本的EASIER研究中得出的经济投入.
主要成果:
- 根据CMA的数据,每名患者节省了2,824欧元 (多发性硬化中心),1,137欧元 (患者) 和9,170欧元 (社会).
- 根据BIA的预测,在补偿后的3年内,MS中心将节省320万欧元,社会节省1030万欧元.
- 与IV相比,SC natalizumab表现出较弱的主导地位,成本较低,有效性不低于IV.
结论:
- 皮下使用纳塔利祖马布可以节省大量的时间和成本.
- 采用SC natalizumab对MS中心,患者和社会产生有利的经济影响.
- 这一分析支持SC natalizumab在意大利医疗保健环境中的成本效益.
关键词:
在MS中心的MS中心.静脉内注射的纳塔利祖马布 (Natalizumab) 已经开始使用.多发性硬化症多发性硬化症从患者的角度来看.社会视角 社会的视角 社会视角在皮下注射 natalizumab.更多相关视频
10:46A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
10.6K
05:44Author Spotlight: Creating a Versatile Experimental Autoimmune Encephalomyelitis Model Relevant for Both Male and Female Mice
Published on: October 13, 2023
1.2K
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
